

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Company

Canntab Therapeutics Limited (“Canntab”)
223 Riviera Drive
Markham, Ontario, L3R 5J6

Item 2: Date of Material Change

July 31, 2022.

Item 3: News Release

A news release with respect to the material change referred to in this report was disseminated on August 2, 2022 through Cision and filed on the system for electronic document analysis and retrieval (SEDAR) at www.sedar.com.

Item 4: Summary of Material Change

Effective July 31, 2022, Richard Goldstein, currently serving as Canntab’s CFO, has been appointed as interim CEO of Canntab.

Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced.

Item 5.1: Full Description of Material Change

The material change is fully described in the news release attached hereto as Schedule “A”.

Item 5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102 (Confidentiality)

Not applicable.

Item 7: Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8: Executive Officer

Canntab Therapeutics Limited

Richard Goldstein

Interim Chief Executive Officer and Chief Financial Officer

Tel: +1 833 301-3812

Email: richard@canntab.ca

Item 9: Date of Report

This report is dated as of the 10th day of August, 2022.

SCHEDULE "A"

(See attached.)



Canntab Therapeutics Ltd.
For immediate release
August 2, 2022

CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO

TORONTO, August 2, 2022 – Canntab Therapeutics Limited ([CSE:PILL.CN](#))([OTCQB:CTABF](#)) ([FRA:TBF1.F](#)) (the “**Company**” or “**Canntab**”), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein, currently serving as Canntab’s CFO, as interim CEO of Canntab, effective July 31, 2022.

Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced.

The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.

About Canntab Therapeutics

Canntab is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These include once a day and extended-release formulations, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License and a Cannabis Research License.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Forward Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the future plans and goals of the Company; the Company's proprietary hard pill cannabinoid formulations providing doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world; the Company's product offerings including once a day and extended-release formulations, both providing an accurate dose and improved shelf stability; and the Company's search for a permanent replacement CEO.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the continued commercial viability, adoption and growth in popularity of the Company's products; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; the Company continuing to develop products; continued growth of the Company; the Company hitting its future plans and goals; the Company's proprietary hard pill cannabinoid formulations providing doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world; the Company's product offerings to continue to include once a day and extended-release formulations, that provides an accurate dose and improved shelf stability; and the Company's ability to attract and engage a qualified and suitable candidate to serve as its permanent replacement CEO.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the industry; risks that the Company will be unable to execute its plans and/or meet its goals; risk that the Company will not grow as anticipated; risks that consumers will not purchase its products; the Company's proprietary hard pill cannabinoid formulations' inability to provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world; the Company's product offerings to no longer include once a day and extended-release formulations, that provides an accurate dose and improved shelf stability; and the inability of the Company to attract and engage a qualified and suitable candidate to serve as its permanent replacement CEO.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

For further information:

Canntab Therapeutics Limited

Richard Goldstein

Interim Chief Executive Officer and Chief Financial Officer

+1 833 301-3812

richard@canntab.ca